News
-
Covis Pharma will pay AstraZeneca $270 million for global rights to the Eklira (Turdorza, Bretaris) aclidinium bromide and Duaklir (Brimica) aclidinium bromide/formoterol DPIs, the companies have announced. Both DPIs are marketed for the treatment of COPD. In addition to… Read more . . .
-
Marinomed Biotech has announced that it signed a distribution agreement with Perrigo for its Carragelose iota-carrageenan nasal spray, and Perrigo has already launched the product in Finland, Norway, Sweden and France. The OTC nasal spray… Read more . . .
-
Armata Pharmaceuticals announced that the Cystic Fibrosis Foundation has purchased $3 million worth of the company’s common stock and that Innoviva subsidiary Innoviva Strategic Opportunities, which already held a significant number of shares in Armata,… Read more . . .
-
According to TFF Pharmaceuticals, Health Canada has issued a no objection letter regarding a Phase 1 clinical trial of TFF’s dry powder inhaled niclosamide that will evaluate 0.5, 2, and 6 mg doses in healthy volunteers… Read more . . .
-
Inhaler testing equipment company Copley Scientific is introducing a new nasal dose uniformity sampling apparatus (DUSA) interface plate designed to work with the company’s Vertus II/Plus shake and fire system for delivered dose uniformity testing… Read more . . .
-
Meissa Vaccines has announced that interim data from a Phase 1 study of its MV-014-212 intranasal recombinant live attenuated COVID-19 vaccine demonstrate that a single dose produced a good nasal IgA response with no reported… Read more . . .
-
Device company Nemera has announced the launch of a new single metered dose nasal pump called UniSpray, which is designed for delivery of systemic drugs. According to the company, UniSpray requires no priming, is compatible… Read more . . .
-
Why should inhaled drug developers consider formulating or reformulating with HFA 152a? It became very clear to us about 6 or 7 years ago that regulatory efforts to reduce global warming potential emissions in industrial… Read more . . .
-
Device developer Cambridge Healthcare Innovations (CHI) has announced the appointment of former AuroScience Head of Device Development Philip Canner as CEO. In addition to AuroScience, an Aurobindo subsidiary that develops generic inhaled drugs, Canner’s OINDP… Read more . . .
-
According to Inhalation Sciences (ISAB), a US patent covering the XposeALI in vitro cell culturing module has been extended until 2034. US Patent No. 11054414 (“Exposure system”) was originally filed in 2013, the company said. The… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
September 15-September 18: DDL New Researcher Network Summer Event, London, UK
September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden